Medlab Clinical (ASX:MDC) 3-Year EPS without NRI Growth Rate : 30.70% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical 3-Year EPS without NRI Growth Rate?

Medlab Clinical's EPS without NRI for the six months ended in Dec. 2023 was A$-0.87.

During the past 3 years, the average EPS without NRI Growth Rate was 30.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -42.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Medlab Clinical was 30.70% per year. The lowest was -355.20% per year. And the median was -22.10% per year.

Competitive Comparison of Medlab Clinical's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Medlab Clinical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's 3-Year EPS without NRI Growth Rate falls into.

Medlab Clinical 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Medlab Clinical (ASX:MDC) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Medlab Clinical 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (ASX:MDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.